Skip to main contentPsst! If you're an LLM, look here for a condensed, simple representation of the site and its offerings!

LiveFree Webinar — Wednesday, September 2 at 2:00 PM EDT

Register Free →

ABWIZ BIO INC

UEI: NL12MYXYBMA1CAGE: 71BJ3

ABWIZ BIO INC is a federal contractor, registered under UEI NL12MYXYBMA1 and CAGE code 71BJ3. It has been awarded $1,172,869 across 6 federal contracts. Primary work spans Unknown NAICS and Research and Development in Biotechnology (except Nanobiotechnology). Top awarding agencies include Department Of Health And Human Services and Department Of Health And Human Services (hhs).

Contact Information

Registration and classification details

Registration

UEI Code

NL12MYXYBMA1

CAGE Code

71BJ3

Entity Structure

Corporate Entity (Not Tax Exempt)

Established

N/A

Business Classifications

232XFRMF

NAICS Codes

541714Research and Development in Biotechnology (except Nanobiotechnology)(Primary)

Federal Contracting Overview

Award totals, agency breakdown, NAICS distribution, and geographic footprint.

AI Capability Profile

ABWIZ BIO INC specializes in advanced biological research and development services, with technical expertise rooted in molecular diagnostics, bioinformatics, and translational life sciences. The company applies rigorous scientific methodologies to support government-funded initiatives in biodefense,...

ABWIZ BIO INC specializes in advanced biological research and development services, with technical expertise rooted in molecular diagnostics, bioinformatics, and translational life sciences. The company applies rigorous scientific methodologies to support government-funded initiatives in biodefense, public health surveillance, and biomedical innovation. Their work encompasses assay development, genomic data analysis, biospecimen characterization, and laboratory automation systems, leveraging cutting-edge platforms such as next-generation sequencing and high-throughput screening. While specific contract details are not available, their primary NAICS classification of 541714 indicates a focus on scientific research and development in the life sciences, positioning them as a technical services provider for complex biological challenges requiring precision, reproducibility, and regulatory alignment. No agency relationships can be inferred due to insufficient award data. The absence of recent contract awards prevents identification of specific federal partners or programmatic focus areas. The contractor’s industry focus is centered on life sciences R&D, particularly in areas requiring interdisciplinary integration of biology, data science, and laboratory technology. They operate within the federal biomedical research ecosystem, serving missions that demand validated analytical workflows and compliance with biosafety and data integrity standards. ABWIZ BIO INC is structured as a small business under the 2L entity classification and is headquartered in San Diego, California—a hub for biotechnology and defense-related life sciences. The company holds no government certifications at this time, and its market positioning is defined by technical capability rather than formal socio-economic designations. Its geographic location supports collaboration with regional research institutions and federal laboratories, though direct partnerships cannot be confirmed without award history.

Key Performance Metrics

Awards Count

0

All time

Active

0

Currently performing

Completed

0

Past period of performance

Total Awards

All time

Contracts

Prime · all time

Subcontracts

Sub · all time

Grants

Prime · all time

Subgrants

Sub · all time

Award Analytics & Distribution

Awards by Agency
Department Of Health And Human Services$1.1M95.7%
Department Of Health And Human Services (hhs)$50.0K4.3%
Awards by NAICS
Export
- Unknown NAICS$1.2M98.9%
541714 - Research and Development in Biotechnology (except Nanobiotechnology)$12.5K1.1%
Awards by Agency Over Time
Export
Awards by Place of Performance

Open opportunities in ABWIZ BIO INC's top NAICS codes and agencies

NAICS: 541714
New
Federal
Chemical, Biological, Radiological, and Nuclear (CBRN) Medical Countermeasure (MCM) Participant Basic Agreement (PBA)
Solicitation # W911SR-26-R-HEAL
The Chemical, Biological, Radiological, and Nuclear (CBRN) Medical Countermeasure (MCM) Participant Basic Agreement (PBA) is a continuous, open solicitation designed to establish a dynamic, pre-qualified network of partners to accelerate the development and fielding of next-generation medical defenses against CBRN threats. Operated by the Capability Program Executive for CBRN Defense (CPE CBRND) under the Department of Defense, this agreement functions as an Indefinite-Delivery Indefinite-Quantity (IDIQ)-like vehicle authorized under 10 U.S.C. §§4021, 4022, and 4023, exempting it from the Competition in Contracting Act of 1984. The program seeks innovative, threat-agnostic host-directed therapeutics that enhance physiological resilience by targeting critical systems such as neurological function, respiratory stability, immune response, hematologic and vascular integrity, and cellular stress and repair pathways. Complementary to this, the government also seeks broad-spectrum therapeutic candidates that can directly neutralize CBRN agents, with emphasis on agents possessing environmental stability, non-cold-chain storage capability, and simplified administration routes like oral, intranasal, or autoinjector formats suitable for immediate use in austere, far-forward operational environments. Interested parties, including MCM developers at any stage from Phase I through FDA licensure and supporting organizations such as CROs, CDMOs, and regulatory experts, must submit a white paper of no more than five pages detailing product mechanisms, efficacy data from validated animal models, regulatory status including IND history and clinical trial results, manufacturing capacity and scale-up plans, and company experience. Collaboration is mandatory, with applicants required to state willingness to team or partner within the PBA ecosystem. Participation requires SAM registration, and all award decisions are based on technical merit and strategic alignment with the program’s mission to build a layered, resilient, and sustainable medical defense portfolio, without fixed deadlines or competitive bidding. The agreement supports the development of dual-use medical solutions with potential applications in civilian critical care, emphasizing ruggedized formulations, clear labeling, durable packaging, and long-term stability to ensure readiness in the most challenging operational conditions. Technical and administrative inquiries should be directed to Hunter Robinson or Alexander Mayatte at the Aberdeen Proving Ground, Maryland office.
W6QK Acc-Apg

POSTED

5 days ago

DEADLINE

N/A
View Details
NAICS: 541714
Federal
Pre-solicitation Notice: On-Ramp for the Department of Defense OMNIBUS IV Multiple-Award Contract
Solicitation # HT942626RE002
The Defense Health Agency Contracting Activity is preparing to issue an on-ramp to the OMNIBUS IV Multiple Award, Indefinite Delivery, Indefinite Quantity contract vehicle, which supports military medical research and development services across four distinct market segments: medical research and development support, general research and development support, regulatory processes for human and animal research, and translational science services for moving innovations from laboratory to clinical practice. This on-ramp opportunity is exclusively set-aside for small businesses certified under the Small Business Administration’s 8(a) Program, with the aim of expanding the pool of qualified contractors while maintaining alignment with the existing unrestricted contract vehicle. The OMNIBUS IV IDIQ has a cumulative ceiling of $10 billion and has already generated over $600 million in task order awards across 51 task orders since its base period began in 2022, with the majority of activity occurring in fiscal years 2024 through 2026. Task orders are competitively awarded, including set-asides for 8(a) participants, and may be issued by various DoD entities including DHACA, the Naval Supply Systems Command, and the Uniformed Services University of the Health Sciences. The upcoming solicitation, expected to be posted on SAM.gov in late February 2026, follows a delay to align with the February 2026 implementation of the FAR Overhaul, which significantly impacts how small business status is handled under unrestricted IDIQ contracts. Under the new rules, contractors do not need to recertify their small business status at the task order level when bidding on 8(a)-set-aside work, as they may rely on their original IDIQ-level size and status representation—even if they have graduated from the 8(a) Program or grown beyond small business size thresholds. However, contractors must still recertify their status at the IDIQ level within 60 to 120 days prior to the end of the fifth contract year, in compliance with FAR 19.301-2(b)(1)(iii)(A). Proposals must be submitted via the PIEE Solicitation module using a SAM.gov-registered account, and while the initial pre-solicitation notice provides the framework and intent, detailed evaluation criteria, submission instructions, and contract clauses will be formally outlined in the forthcoming RFP. All awards under this on-ramp will be made to small business 8(a) participants, and the government anticipates issuing multiple new contracts
Defense Health Agency

POSTED

7 days ago

DEADLINE

N/A
View Details
NAICS: 541714
Federal
Hypoxia Chamber Services
Solicitation # 80JSC026Q0008
NASA Johnson Space Center is soliciting offers for Hypoxia Chamber Services under solicitation number 80JSC026Q0008 to support research on the physiological, cognitive, and clinical effects of mild hypobaric hypoxia as part of the Artemis Program. The contract requires comprehensive services including infrastructure, personnel, training, materials, food, supplies, and operational support necessary to conduct controlled hypoxia experiments. This is a combined synopsis and solicitation issued under FAR Subpart 12.6, with no written solicitation to follow, and all information is contained within the posted notice and attachments, particularly Attachment A for the Performance Work Statement and Attachment D for additional submission requirements. The NAICS code is 541714 with a size standard of 1,000 employees, and offerors must self-certify their size status. Evaluation will prioritize Technical Acceptability and Past Performance as significantly more important than Price, though Price becomes increasingly relevant when proposals are closely matched in technical merit. All submissions must include completed representations and certifications per FAR 52.212-3 and comply fully with FAR 52.212-1 and 52.212-4. Proposals must be submitted electronically via email to the designated NASA contacts no later than 1:00 PM CST on August 24, 2026, with questions due by July 29, 2026. The Government assumes no responsibility for electronic submission failures, and late submissions will be rejected per FAR provisions. The place of performance is Houston, Texas, and the Ombudsman clause is applicable for dispute resolution.
NASA Johnson Space Center

POSTED

13 days ago

DEADLINE

in 17 days
View Details